8-bromo-2,2,4,4-tetramethyl-6-chromanoic acid | 191469-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 8-bromo-2,2,4,4-tetramethyl-6-chromanoic acid
• 英文别名: 8-bromo-2,2,4,4tetramethyl-6-chromanoic acid；8-bromo-2,2,4,4-tetramethyl-3H-chromene-6-carboxylic acid
• CAS: 191469-37-1
• 化学式: C₁₄H₁₇BrO₃
• 分子量: 313.191
• InChiKey: NTVVCEGIGSIJPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-bromo-2,2,4,4-tetramethyl-6-chromanoic acid 、 4-氨基-2-氟苯甲酸乙酯 以 吡啶 、 二氯甲烷 为溶剂， 生成 Ethyl 2-fluoro-4-[(2',2;4,4'-tetramethyl-8'-bromochroman-6'-yl)carbamoyl]benzoate
  参考文献：
  名称：

  Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity

  摘要：

  该式化合物具有类视黄醇生物活性，其中符号的含义在规范中定义。

  公开号：

  US06342602B1
• 作为产物：
  描述：

  2,2,4,4-Tetramethyl-chroman-6-carboxylic Acid 在 溴 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 8-bromo-2,2,4,4-tetramethyl-6-chromanoic acid
  参考文献：
  名称：

  Methods of treatment with compounds having RAR.sub..alpha. receptor

  摘要：

  对RAR.sub..alpha.受体亚型具有特异性或选择性作用，优先于RAR.sub..beta.和RAR.sub..gamma.受体亚型的视黄醇类化合物具有与视黄醇相关的理想药理特性，并特别适用于治疗肿瘤，如急性单核细胞白血病、宫颈癌、骨髓瘤、卵巢癌和头颈癌，而不会产生视黄醇的一个或多个不良副作用，如诱导体重减轻、粘膜皮肤毒性、皮肤刺激和致畸性。

  公开号：

  US05965606A1

文献信息

• Methods of treatment with compounds having RAR.sub..alpha. receptor
  申请人：Allergan Sales, Inc.

  公开号：US05965606A1

  公开（公告）日：1999-10-12

  Retinoid compounds which act specifically or selectively on RAR.sub..alpha. receptor subtypes in preference over RAR.sub..beta. and RAR.sub..gamma. receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.

  对RAR.sub..alpha.受体亚型具有特异性或选择性作用，优先于RAR.sub..beta.和RAR.sub..gamma.受体亚型的视黄醇类化合物具有与视黄醇相关的理想药理特性，并特别适用于治疗肿瘤，如急性单核细胞白血病、宫颈癌、骨髓瘤、卵巢癌和头颈癌，而不会产生视黄醇的一个或多个不良副作用，如诱导体重减轻、粘膜皮肤毒性、皮肤刺激和致畸性。
• Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman
  申请人：Allergan

  公开号：US05675024A1

  公开（公告）日：1997-10-07

  Compounds of the formula ##STR1## where the symbols have the meaning defined in the specification have retinoid-like biological activity.

  式子##STR1##中的符号具有规范中定义的含义，化合物具有类视黄醇生物活性。
• Methods of treatment with compounds having RAR alpha receptor specific or selective activity
  申请人：Allergan Sales, Inc.

  公开号：US20020077360A1

  公开（公告）日：2002-06-20

  Retinoid compounds which act specifically or selectively on RAR &agr; receptor subtypes in preference over RAR &bgr; and RAR &Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.

  作用于RARα亚型的视黄酸类化合物，具有优于RARβ和RARγ亚型的选择性或特异性，具有与视黄酸相关的理想药物特性，特别适用于治疗肿瘤，如急性单核细胞白血病、宫颈癌、骨髓瘤、卵巢癌和头颈癌，而不具有视黄酸的一个或多个不良副作用，如诱导体重减轻、粘膜皮肤毒性、皮肤刺激和致畸性。
• Methods of treatment with compounds having RAR&agr; receptor specific or selective activity
  申请人：Allergan, Inc.

  公开号：US06610744B2

  公开（公告）日：2003-08-26

  Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.

  对RARα受体亚型具有特异性或选择性作用，而优先于RARβ和RARγ受体亚型的视黄酸类化合物具有与视黄酸相关的理想药物特性，特别适用于治疗肿瘤，例如急性单核细胞白血病、宫颈癌、骨髓瘤、卵巢癌和头颈癌，而不具有视黄酸的一个或多个不良副作用，例如诱导体重减轻、粘膜皮肤毒性、皮肤刺激和致畸性。
• METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
  申请人：Vision Pharmaceuticals L.P.

  公开号：EP0869782A2

  公开（公告）日：1998-10-14